J&J says Inlexzo follow-up 'promising' in bladder cancer Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

#JohnsonandJohnson has revealed early clinical data with a new formulation of its #FGFRinhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage #bladdercancer.

pharmaphorum.com/news/jj-says...